biostudies-literatureJara-Palomares LNEUMOSUR (5/2013); and the LEO Pharma Research Foundation.Sociedad Española de Neumología y Cirugía TorácicaMinistry of Economy and Competitiveness | Instituto de Salud Carlos III915-921https://www.ebi.ac.uk/biostudies/studies/S-EPMC6203717biostudies-literatureUnknown119(8)<h4>Background</h4>Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT.<h4>Methods</h4>Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence.<h4>Results</h4>Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age waBritish journal of cancerD-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.PMC6203717PI15/01085140/2013Solier-Lopez AMarin-Barrera LArellano-Orden ERuiz-Garcia AOtero-Candelera RBlasco-Esquivias IPraena-Fernandez JMSuarez-Valdivia Lde la Borbolla MRAsensio-Cruz MISanchez-Diaz JMElias-Hernandez TSerrano-Gotarredona MPSanchez-Lopez VJara-Palomares LMarin-Romero SLopez-Campos JLMontero-Romero ENavarro-Herrero SfalseD-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.<h4>Background</h4>Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT.<h4>Methods</h4>Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence.<h4>Results</h4>Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age wa2018-01-01T00:00:00Z2018 Oct2026-04-30T05:52:19.262Z2019-10-18T07:02:15ZS-EPMC62037173031850810.1038/s41416-018-0269-5